
    
      Patients having completed the previous 12-week PLEODIAL-I study were eligible to receive
      PXT00864 in this 24-week open-label extension PLEODIAL-II study in order to collect some
      additional long-term data regarding the safety and the potential effect of PXT00864 on
      cognitive and behavioural impairments.
    
  